Journal profile · Urology & Nephrology
Renal Failure
ISSN 0886-022X · eISSN 1525-6049 · Informa Healthcare · UNITED STATES · Bimonthly · Founded 1987
Renal Failure: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.79; JCR Q1 (journal website); fully open access; APC about USD 2,990; median 112 days to acceptance (126 articles, last 24 months); community-reported acceptance: easy; 621 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Renal Failure is published by Informa Healthcare and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Dialysis and Renal Disease Management, Chronic Kidney Disease and Diabetes and Acute Kidney Injury Research, together about 45% of its articles. Its main subfields are Nephrology. (generated from OpenAlex topic counts and CAS ranking data)
Renal Failure is an open access peer-reviewed journal publishing on acute renal injury and its consequences. The primary focus of Renal Failure is acute kidney injury (AKI). This includes the basic sciences and those derived from human studies on the subject. There is a critical need to support the drive for research in this field. The high mortality of AKI in the critically ill is unacceptable. The journal aims to publish methods that have demonstrated improved outcomes of AKI in the critically ill and related research. The journal’s audience includes clinicians, researchers and medical professionals, advanced care practitioners, hospital-based pharmacists, educators, policy makers, technology developers and data scientists, and patients and patient advocates who are interested in nephrology, specifically AKI. Renal Failure also publishes advances in the fields of chronic renal failure, hypertension and renal transplantation. The journal aims to bring together clinical and experimental aspects of renal failure to present timely, practical information on a variety of topics: Pathology and pathophysiology of acute renal failure Nephrotoxicity of drugs and other substances Prevention, treatment, and therapy of renal failure Transplantation, hypertension, and diabetes mellitus in association with renal failure Renal Failure accepts Clinical Studies, Laboratory Studies, State-of-the-Art Review Articles, Systematic Reviews, Brief Reports, Comments, Educational Comments, Article Commentaries and Editorials (Editors and Guest Advisors only) for publication. Please check our Instructions for Authors when submitting. Please note that PRISMA guidelines are required for Systematic Reviews, ARRIVE guidelines are mandatory for in vivo animal studies, and STROBE-MR checklists are required upon submission for Mendelian randomization studies. The journal also now has a Share Upon Reasonable Request data sharing policy. The journal welcomes submissions to the following sections: Acute Kidney Injury Anemia and Hematologic Disorders Artificial Intelligence and Machine Learning Basic Sciences Investigations Bone-Mineral and Electrolyte Disorders Cardio-renal Physiology and Disease Processes Chronic Kidney Disease and Progression Critical Care Nephrology and Continuous Kidney Replacement Therapy Educational Comments Glomerulonephritis and Immunologic Disorders Hemodialysis and Peritoneal Dialysis Hypertension and Volume Management Imaging Technologies in Nephrology Medical Edu
From the journal's Aims & Scope
Research area (LetPub): Urology & Nephrology
Editor-in-chief Tibor FülöpPublisher website
Editorial board by country: 23 in mainland China (about 29%); most named Mainland China 23, United States 20, Japan 4, Türkiye 4, Hungary 3 (79 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Dialysis and Renal Disease ManagementMedicine17.2%
- Chronic Kidney Disease and DiabetesMedicine14.3%
- Acute Kidney Injury ResearchMedicine13.6%
- Renal Diseases and GlomerulopathiesMedicine8.5%
- Parathyroid Disorders and TreatmentsMedicine5.5%
- Renal Transplantation Outcomes and TreatmentsMedicine3.4%
- Renal and Vascular PathologiesMedicine2.9%
- Central Venous Catheters and HemodialysisHealth Professions2.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Urology & Nephrology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Urology & Nephrology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Urology & Nephrology | Zone 3 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q1 · best quartile · 2025
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPubMedEmbaseCASCurrent ContentsPublisher website
Other: Academic Search Complete, Biomedical Reference Collection: Comprehensive, Biochemistry and Biophysics Citation Index, Biological Abstracts, BIOSIS Full Coverage Shared, BIOSIS Previews, Derwent Drug File, ETOH, Journal Citation Reports/Science Edition, PASCAL, PopLine, SciSearch, SIIC
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.79LetPub ·
- Impact factor (publisher) 2025
- 3.8Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.7Publisher website ·
- CiteScore 2026-06
- 4.5LetPub ·
- CiteScore (publisher) 2025
- 4.5Publisher website ·
- SJR 2026-06
- 0.95LetPub ·
- SJR (publisher) 2025
- 0.95Publisher website ·
- SNIP 2026-06
- 1.06LetPub ·
- SNIP (publisher) 2025
- 1.06Publisher website ·
- h-index
- 49LetPub ·
- h-index
- 88OpenAlex ·
- i10-index
- 3,047OpenAlex ·
- 2-year mean citedness
- 4.18OpenAlex ·
- Self-citation rate
- 7.9%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 598LetPub ·
- Downloads per year (publisher)
- 2,500,000Publisher website ·
Articles by year OpenAlex count · 6,621 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 356 | 356 | 98 |
| 2025 | 621 | 621 | 2,216 |
| 2024 | 487 | 487 | 3,803 |
| 2023 | 338 | 338 | 3,863 |
| 2022 | 221 | 221 | 3,089 |
| 2021 | 181 | 181 | 2,897 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
112 daysMedian, submission to acceptance · P25–P75 83 days – 172 days
- Acceptance to online
- median 21 days (126 articles)
- Submission to online
- median 151 days
- Sample
- 126 articles with submission and acceptance dates (1,085 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Acceptance rate (publisher)
- 26%Publisher website ·
- Submission to first decision
- 6 daysPublisher website ·
- First decision after review
- 39 daysPublisher website ·
- Acceptance to publication
- 30 daysPublisher website ·
- Submission to publication (journal-reported)
- about 14 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | AUD 4,165 / EUR 2,875 / GBP 2,392 / USD 2,990 | Yes | CC BY, CC BY-NC | |
| OpenAlex | GBP 1,880 | — | — | |
| LetPub | GBP 2,100 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted9
- article commentariesRenal Failure accepts Clinical Studies, Laboratory Studies, State-of-the-Art Review Articles, Systematic Reviews, Brief Reports, Comments, Educational Comments,…Length not stated
- brief reportsRenal Failure accepts Clinical Studies, Laboratory Studies, State-of-the-Art Review Articles, Systematic Reviews, Brief Reports, Comments, Educational Comments,…Length not stated
- clinical studiesRenal Failure accepts Clinical Studies, Laboratory Studies, State-of-the-Art Review Articles, Systematic Reviews, Brief Reports, Comments, Educational Comments,…Length not stated
- commentsRenal Failure accepts Clinical Studies, Laboratory Studies, State-of-the-Art Review Articles, Systematic Reviews, Brief Reports, Comments, Educational Comments,…Length not stated
- editorialsRenal Failure accepts Clinical Studies, Laboratory Studies, State-of-the-Art Review Articles, Systematic Reviews, Brief Reports, Comments, Educational Comments,…Length not stated
- educational commentsRenal Failure accepts Clinical Studies, Laboratory Studies, State-of-the-Art Review Articles, Systematic Reviews, Brief Reports, Comments, Educational Comments,…Length not stated
- laboratory studiesRenal Failure accepts Clinical Studies, Laboratory Studies, State-of-the-Art Review Articles, Systematic Reviews, Brief Reports, Comments, Educational Comments,…Length not stated
- state-of-the-art review articlesRenal Failure accepts Clinical Studies, Laboratory Studies, State-of-the-Art Review Articles, Systematic Reviews, Brief Reports, Comments, Educational Comments,…Length not stated
- systematic reviewsRenal Failure accepts Clinical Studies, Laboratory Studies, State-of-the-Art Review Articles, Systematic Reviews, Brief Reports, Comments, Educational Comments,…Length not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, Open access, Peer review
- Authorship
PRISMA guidelines required for Systematic Reviews; ARRIVE guidelines mandatory for in vivo animal studies; STROBE-MR checklists required upon submission for Mendelian randomization studies. Model summary
Please note that PRISMA guidelines are required for Systematic Reviews, ARRIVE guidelines are mandatory for in vivo animal studies, and STROBE-MR checklists are required upon submission for Mendelian randomization studies.
Source ↗Publisher website ·- Data availability
Share Upon Reasonable Request data sharing policy. Model summary
The journal also now has a Share Upon Reasonable Request data sharing policy.
Source ↗Publisher website ·- Open access Open access
Renal Failure is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readership of your article Make an impact and reach new readers, not just those with easy…
Source ↗Publisher website ·- Peer review
Single-anonymized peer review policy. Model summary
The journal operates a single-anonymized peer review policy.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Informa Healthcare
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1987
- ISSN
- 0886-022X
- Electronic ISSN
- 1525-6049
- Latest issue on the website
- Volume 48, Issue 1 (2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Renal Failure
What CAS zone is Renal Failure in?
In the 2025 upgraded edition of the CAS Journal Ranking, Renal Failure is in Zone 3 of Medicine, and in Zone 3 of the minor category Urology & Nephrology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Renal Failure?
The latest impact factor listed by LetPub is 3.79; CiteScore 4.5, h-index 88.
How long does peer review take at Renal Failure?
Based on the dates recorded on 126 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 112 days (interquartile range 83–172 days); authors report an average review time of about 1 month; the community-reported acceptance is “Easy”; the journal's website gives an acceptance rate of 26%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Renal Failure in?
The journal's website gives JCR Q1 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
Where are the editorial board members of Renal Failure based?
Of the 79 board members whose country the journal's board page names, 23 (about 29%) are in mainland China; the countries named most often are Mainland China (23), United States (20) and Japan (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Renal Failure?
According to LetPub and DOAJ records, Renal Failure is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, PubMed, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Renal Failure open access, and what is the APC?
Renal Failure is a fully open-access journal. APC about USD 2,990.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .